<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774838</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1649</org_study_id>
    <nct_id>NCT01774838</nct_id>
  </id_info>
  <brief_title>Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome</brief_title>
  <official_title>Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the vasoactive and anti-inflammatory effects of prasugrel in patients with acute&#xD;
      coronary syndrome endothelial function -as a surrogate parameter of NO bioavailability- and&#xD;
      different markers of inflammation, oxidative stress and platelet activation will be assessed&#xD;
      in patients with unstable angina.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial Objectives To test the vasoactive and anti-inflammatory effects of prasugrel in&#xD;
      patients with acute coronary syndrome, endothelial function -as a surrogate parameter of NO&#xD;
      bioavailability- and different markers of inflammation, oxidative stress and platelet&#xD;
      activation will be assessed in patients with unstable angina.&#xD;
&#xD;
      Trial Design Single center, double blind, double-dummy, randomized, parallel trial.&#xD;
&#xD;
      Endpoints&#xD;
&#xD;
      Primary Endpoint Assessment of endothelial function (FMD) via high-resolution ultrasound&#xD;
      (Sonoline G50, 12 MHz linear array transducer, Siemens, Germany) by experienced sonographer.&#xD;
&#xD;
      Secondary Endpoints&#xD;
&#xD;
        -  Non-invasive assessment of microvascular perfusion and oxygen saturation by laser&#xD;
           Doppler perfusion imaging and tissue spectrometry (O2C, Lea Medizintechnik, Giessen,&#xD;
           Germany)&#xD;
&#xD;
        -  Determination of leukocyte activity: plasma MPO levels (ELISA), plasma elastase levels&#xD;
           (ELISA)&#xD;
&#xD;
        -  Assessment of platelet activity: plasma levels of sCD40 ligand (ELISA), RANTES (ELISA)&#xD;
&#xD;
        -  Measurement of different oxidative stress markers: hsCRP (ELISA), CD40 ligand (ELISA),&#xD;
           carbonylated proteins (ELISA), urinary 8-iso-PGF2α (gas chromatography mass&#xD;
           spectrometry)&#xD;
&#xD;
        -  Determination of platelet-leukocyte aggregates by fluorescent activated cell sorter&#xD;
           (FACS)&#xD;
&#xD;
        -  Assessment of platelet function (PADA-test)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of endothelial function (FMD) via high-resolution ultrasound (Sonoline G50, 12 MHz linear array transducer, Siemens, Germany) by experienced sonographer</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>The primary endpoint is the change of endothelial function given in % from baseline to 3 months after therapy with prasugrel versus clopidogrel.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months treatment with 10 mg prasugrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 months treatment with clopidogrel 75 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>3 months treatment</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>3 months treatment</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute coronary syndrome, unstable angina&#xD;
&#xD;
          -  planned percutaneous coronary intervention&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Age &lt; 18 years or ≥75 years&#xD;
&#xD;
          -  Body weight &lt; 60 kg&#xD;
&#xD;
          -  STEMI, NSTEMI&#xD;
&#xD;
          -  Cardiogenic shock at the time of randomization&#xD;
&#xD;
          -  Refractory ventricular arrhythmias&#xD;
&#xD;
          -  Congestive heart failure (NYHA IV)&#xD;
&#xD;
          -  Increased risk of bleeding&#xD;
&#xD;
          -  Active internal bleeding or history of hemorrhagic diathesis&#xD;
&#xD;
          -  History of TIA, ischemic or hemorrhagic stroke&#xD;
&#xD;
          -  Intracranial neoplasm, aneurysm and arteriovenous malformation&#xD;
&#xD;
          -  INR &gt; 1.5 at screening&#xD;
&#xD;
          -  Platelets &lt; 100,000/ml&#xD;
&#xD;
          -  Anemia (Hb &lt; 10 g/dl) at screening&#xD;
&#xD;
          -  One or more doses of a thienopyridine 5 d or less before PCI&#xD;
&#xD;
          -  Oral anticoagulation which cannot be safely discontinued for the duration of the study&#xD;
&#xD;
          -  One or more doses of a thienopyridine 5 d or less before PCI&#xD;
&#xD;
          -  Treatment within the last 30 d with an investigational drug or are presently enrolled&#xD;
             in another drug or device study&#xD;
&#xD;
          -  Women who are known to be pregnant, have given birth within the past 90 d, or are&#xD;
             breast-feeding&#xD;
&#xD;
          -  Concomitant medical illness that in the opinion of the investigator is associated with&#xD;
             reduced survival over the expected treatment period&#xD;
&#xD;
          -  Known severe hepatic dysfunction&#xD;
&#xD;
          -  Any condition associated with poor treatment compliance, including alcoholism, mental&#xD;
             illness, or drug dependence&#xD;
&#xD;
          -  Intolerance of or allergy to aspirin, ticlopidine, or clopidogrel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Rudolph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology, University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Tanja Rudolph</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

